Responsible to research and development assessment of new biotech projects and verification studies for identified new technology.

Founder of Regenerative Medicine Co. Ltd that has been in continuous operation for 14 years in Asia. Our primary focus is " living medicine " and advanced biotech treatments such as stem cells and biomolecules that are new to the medical community and doctors. We focus exclusively on clinically proven technologies and undertake strict independent due diligence to ensure substances and products are bioavailable, active, safe and effective for physicians as well as patients. We act as your new product development and due diligence team.

Promoted by Bumrungrad Hospital to head their Integrative Wellness Center. Consulted on the renovation of the largest anti-aging clinic and associated biomedicine lab in Southeast Asia. Executed a rebranding initiative with an International Swiss firm to update clinic image. Coordinating with Dr. Terry Grossman to develop new product strategy.-Supported the setup of an Integrative Cancer Center based on a global evaluation of the most cutting-edge treatments and therapies. -Spearheaded the setup of a stem cell lab to provide the clinic with regenerative medicine treatments and assessment of the latest biologic therapies for both cancer and stem cell applications. -Directed software development team engaged in digitizing clinical practices along with the development of an application to assist clinicians in Anti-aging, Wellness, Detoxification and Regenerative Medicine. -Oversaw gene-sequencing lab (NGS) to help develop tailored Wellness gene panels for precision medicine initiative, personalized medicine, and pharmacogenomics offerings at both the clinic and the hospital.

Established relationships with the worlds most advanced healthcare technologies including Artificial Intelligence (AI), Next Generation Sequencing (NGS), cell therapies/biotech and cancer centers globally. Supported international expansion plans to enter the European market for Bumrungrad Hospital. Traveled extensively to Europe and the Middle East to assess healthcare landscape, potential partners and locations for a Regenerative and Precision Medicine Clinic. -Initiated due diligence on new healthcare biotechnologies with a focus on stem cells and Immunotherapies in the United States, Europe and Asia.-Finalized contracts to transfer technologies to Thailand for use at the institution’s biomedicine lab.-Negotiated business deals with university, private biotech and healthcare firms to license products or conduct clinical trials to acquire Thai FDA approval. -Successfully oversaw equipment selection, purchase and NGS lab setup including production of clinical gene sequencing.

Spearheaded the initial global launch of the Adi-light LED and stem cell kits in March 2010. Enabled Adistem expansion to 6 continents and 54 countries over 4 years by negotiating distribution agreements. Interviewed on EU and Asian television to discuss Clinical Trials and to educate the public about the groundbreaking technology.-Collaborated closely with principal investigators to implement the Orthopedic and the Idiopathic Pulmonary Fibrosis Clinical Trials in the EU. -Directly responsible for submission and Regulatory Approvals of cell therapy products with global FDA organizations.-Maintained continued relationships with major hospital groups including the Parkway Group, Bumrungrad International, Bangkok Hospital Group and Apollo Hospital Group. -Provided their physicians with the innovative technology used to treat Tiger Woods, Bartolo Colon and Madonna.

Primary driving force in building the web portal to assist patients, doctors and hospitals with the ability to capitalize on stem cell therapy. Successfully signed exclusive distribution agreements with Stem Cell Companies, executed Clinical Trials and obtained Thai FDA certification and registration for several cell-based products.-Conducted due diligence and presented Stem Cell Companies to Executive Management Teams and Key doctors. -Led the organization in its distribution of cellular-based medicine in Thailand.-Oversaw a formal Clinical Trial at Chulalongkorn University with the Queen Sirikit Center for Breast Cancer in Bangkok.

Presented and collaborated on investment offerings to partner hospital groups, such as the Parkway Hospital Group, Singapore (15 hospitals), and the Dusit Hospital Group, Thailand (52 hospitals). Initiated business development contacts and presented to Boards and Medical staff on Regenerative Medicine Program guidelines and stem cell technologies to Phaya Thai (13 Hospitals), Chao Phraya, and Praram 9 Hospital. -Assembled technical presentation materials with Professor Yael Porat for Israeli stem cell lab. -Pioneered Cell Therapy Programs for Cardiovascular (Chronic Ischemia and Cardiomyopathy) and Peripheral Artery Disease Indications at partner hospitals in Asia.-Established databases on global stem cell companies, clinical trials, distribution networks and the latest technological and regulatory developments.

Formulated plans and strategies for regional business opportunities in target markets of Singapore, Vietnam and Hong Kong. Conducted business development activities and managed sales and marketing staff. Assessed partnership and reseller opportunities for IT solutions.